AU Patent

AU2019369843A2 — Edaravone suspension for oral administration

Assigned to Tanabe Pharma Corp · Expires 2023-02-02 · 3y expired

What this patent protects

Provided is an edaravone suspension for oral administration that has excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby.

USPTO Abstract

Provided is an edaravone suspension for oral administration that has excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019369843A2
Jurisdiction
AU
Classification
—
Expires
2023-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.